WHO needs more information from Bharat Biotech for Covaxin
WHO said it expects additional information from Indian vaccine maker Bharat Biotech as it pursues an emergency-use listing of its COVID-19 vaccine. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

MSN Labs launches patented diabetes pill Jardiance after DRL, heats up potential legal battle
Earlier, ET reported that Dr Reddy's Labs has launched copies of Jardiance. It has a valid patent in India until 2025. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

PharmEasy closes $350 million in pre-IPO round, valuation jumps to $5.6 billion
Online pharmacy PharmEasy has closed a funding round worth nearly $350 million ahead of filing its draft red herring prospectus (DRHP) before an Initial Public Offering (IPO), according to regulatory documents sourced by ET and people briefed on the matter. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

Dr Reddy's Labs launches copy of BI drug; move may lead to legal battle
Under its brand Vicra, Dr. Reddy's is expected to sell the drug in India at less than a third of the price charged by Boehringer Ingelheim. According to sources the 10 mg variant of Dr. Reddy's brand may cost ₹15 per tablet against ₹51 of the innovator's brand. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

Mix-and-match vaccines highly effective against COVID-19: Lancet study
Since the use of AstraZeneca's vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

WHO advisory group to meet on Oct 26 to decide on Bharat Biotech ’s Covaxin
“The technical advisory group will meet on Oct 26th to consider EUL for Covaxin,” WHO’s chief scientist Soumya Swaminathan said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 17, 2021 Category: Pharmaceuticals Source Type: news

Made in India virus kits boost testing, and local industry
Over a year later, most Indians can access PCR tests at a fraction of the cost - due to a large-scale public-private partnership, known as InDx, that set up the local know-how and infrastructure to manufacture these tests within India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 15, 2021 Category: Pharmaceuticals Source Type: news

Ivermectin is a Nobel Prize-winning wonder drug – but not for COVID-19
Ivermectin, when used correctly, has prevented millions of potentially fatal and debilitating infectious diseases. It's meant to be prescribed only to treat infections caused by parasites. It's not meant to be prescribed by parasites looking to extract money from desperate people during a pandemic. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 15, 2021 Category: Pharmaceuticals Source Type: news

Covid-19 outbreak in Delhi shows herd immunity against Delta variant difficult: Study
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 15, 2021 Category: Pharmaceuticals Source Type: news

Colorcon buys TA-backed pharma firm Ideal Cures
​​TA Associates, which has invested in more than 500 companies around the globe, has a wide exposure in India with investments such as Indira IVF, Dr Lal Pathlabs, OmniActive and TCNS Clothing which sells W brand. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 14, 2021 Category: Pharmaceuticals Source Type: news

Bharat Bio hopes to soon submit trial data for intranasal vaccine
"The trials are ongoing, and we expect to submit data by the end of this year," a company insider said. The trials, including over 600 participants, are being conducted by dividing the volunteers into three groups. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 14, 2021 Category: Pharmaceuticals Source Type: news

Single jab Sputnik Light shows 70% efficacy against Delta: RDIF
The data used in the study was collected in July 2021 in Moscow. Gamelya said it has submitted the data to non peer reviewed medical journal medRxiv. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 13, 2021 Category: Pharmaceuticals Source Type: news

New toxic drug impurities detected in some heart pills in US
The impurities were found in blood pressure drugs which have been recalled in Canada as well as Europe earlier this year. U.S. officials helped lead the way in the 2018 recalls of the same type of drugs tainted with the probable carcinogen N-Nitrosodimethylamine, or NDMA, though they have yet to pull any for containing the azido impurities. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 13, 2021 Category: Pharmaceuticals Source Type: news

Rakesh Jhunjhunwala exits underperforming pharma bet in Q2
Jhunjhunwala held 72,45,605 equity shares or 1.6 per cent stake in the company as of June 30, 2021. Companies are not obliged to reveal names of shareholders who hold less than 1 per cent stake in a firm. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 13, 2021 Category: Pharmaceuticals Source Type: news

Taking care of your feet if you have diabetes
Neglecting your feet if you are diabetic can result in some serious complications. Keep your blood sugar levels within a good range. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 13, 2021 Category: Pharmaceuticals Source Type: news

Right pricing to hold the key for Zydus Cadila's vaccine launch
Zydus Cadila has the drug regulator's emergency use authorisation to administer its Covid vaccine, ZyCoV-D, in children aged 12-18 years. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 13, 2021 Category: Pharmaceuticals Source Type: news

Aspirin use to prevent 1st heart attack or stroke should be curtailed, US panel says
The U.S. panel also plans to retreat from its 2016 recommendation to take baby aspirin for the prevention of colorectal cancer, guidance that was groundbreaking at the time. The panel said that more recent data had raised questions about the putative benefits for cancer, and that more research was needed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

India's Everest Organics starts making ingredient for Merck's COVID-19 pill
The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately entered into voluntary licensing agreements with at least eight Indian generic drugmakers for molnupiravir, with an aim to turn the country into a manufacturing hub for the drug. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

Covaxin gets emergency use approval for kids
Hyderabad-based pharma major Bharat Biotech's Covaxin got the emergency use approval for children in the age group of 2 to 18 years from the Drugs Controller General of India. The Subject Expert Committee on Covid-19 gave the approval for the emergency use in the children. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

Awaiting regulatory approvals to launch Covaxin for children: Bharat Biotech
"This represents one of the first approvals worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children," Bharat Biotech said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

Biological E seeks DCGI's nod for phase-3 trial of Corbevax as booster dose in those vaccinated with Covishield or Covaxin
Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

As input costs soar, small drug units reach out to Centre for help
The prices of active pharmaceutical ingredients (APIs), excipients, glass vials and packaging material, among other inputs, have escalated over the last three months. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

What the future holds for the Coronavirus and us
Even for a virus, evolution is a long game, and our relationship with SARS-CoV-2 is still in its infancy. We are extremely unlikely to eradicate the virus, scientists say, and what the next few years — and decades — hold is difficult to predict. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 12, 2021 Category: Pharmaceuticals Source Type: news

Eli Lilly lays off 120 employees in India after Cipla sale
The sales team was informed of the decision at a virtual town hall organised last week in conjunction with the media announcement of the deal with Cipla. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 11, 2021 Category: Pharmaceuticals Source Type: news

AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19
"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months," said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 11, 2021 Category: Pharmaceuticals Source Type: news

Cumulative COVID-19 vaccine doses given in India surpass 95 crore mark
According to sources, the government has permitted the export of Russia's single-dose COVID-19 vaccine Sputnik Light domestically produced here as the jab has not yet been approved for emergency use in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 10, 2021 Category: Pharmaceuticals Source Type: news

NMPB inks deal with IHBT for production of planting material for medicinal plants
Established under the Ministry of Ayush, the NMPB works towards supporting policies and programmes for the growth of trade, export, conservation and cultivation of medicinal plants, a statement issued by the Ayush ministry said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 9, 2021 Category: Pharmaceuticals Source Type: news

IT department detects Rs 550 crore in hidden income after raids on Hetero pharma group
"During the search, several bank lockers have been found, out of which 16 lockers have been operated. The searches have resulted in the seizure of unexplained cash amounting to Rs 142.87 crore, so far," the Central Board of Direct Taxes (CBDT) said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 9, 2021 Category: Pharmaceuticals Source Type: news

Eye care chain Dr Agarwals plans to spend Rs 1,000 crore to expand presence
Dr Agarwals operates 100 eye hospitals, of which 86 are in India and the remaining in Africa. It has clinics in Mauritius, Mozambique, Tanzania, Rwanda and Uganda. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 9, 2021 Category: Pharmaceuticals Source Type: news

Export curbs on Covid diagnostic kits revoked
At a meeting last week, one of the empowered groups on Covid-19 management recommended that export restrictions be lifted from Covid-19 diagnostic kits and free export of these products be allowed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 9, 2021 Category: Pharmaceuticals Source Type: news

Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravir
In a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients and continue the phase III trial in mild Covid patients", as per the minutes of the meeting. ET has seen the minutes of the SEC meeting. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 8, 2021 Category: Pharmaceuticals Source Type: news

Wockhardt jumps 11% amidst stake sale buzz
Reports said Covishiled manufacturer SII may buy 10 per cent stake, valuing the Wockhardt at Rs 7,000 crore. The current market-cap of the company stands at Rs 5,691.08 crore. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 8, 2021 Category: Pharmaceuticals Source Type: news

Two Indian drugmakers seek to end trials of Merck's antiviral drug for moderate COVID-19
The two Indian drugmakers, Aurobindo Pharma and MSN Laboratories plan to continue late-stage trails of the drug for those with mild COVID-19. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 8, 2021 Category: Pharmaceuticals Source Type: news

Gland Pharma gets tentative nod from USFDA for generic Sugammadex injection
The company "has received tentative approval from the United States Food and Drug Administration (USFDA) for Sugammadex injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial...", Gland Pharma said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 8, 2021 Category: Pharmaceuticals Source Type: news

SII gets nod to send Covid vaccines to Nepal, Bangaldesh, Myanmar, bulk to AstraZeneca; Bharat Biotech to Iran
Union Health Minister Mansukh Mandaviya on September 20 announced that India will resume export of surplus COVID-19 vaccines in the fourth quarter of 2021 under the 'Vaccine Maitri' programme and to meet its commitment to the COVAX global pool. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2021 Category: Pharmaceuticals Source Type: news

Piramal board okays demerger of pharma, financial services operations
The amalgamation of PHL Fininvest Private Limited with PEL will create a listed non-banking financial services (NBFC) entity. The merged housing finance company (HFC) post DHFL acquisition will remain a 100 per cent subsidiary of PEL. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2021 Category: Pharmaceuticals Source Type: news

Bharat Biotech to produce world's 1st malaria vaccine approved by WHO
Earlier, WHO endorsed the world's first malaria vaccine and said it should be given to children across Africa in the hope that it will spur stalled efforts to curb the spread of the parasitic disease. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2021 Category: Pharmaceuticals Source Type: news

Dr Reddy's finding it hard to sell Russian-made Sputnik V vaccine in India
"In terms of the market situation, the private market overall has seen a sharp dip and Sputnik V has been solely private. The market has seen scale-up in overall vaccine production in India and free distribution through the government," Dr Reddy's said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2021 Category: Pharmaceuticals Source Type: news

Panel for removing penal provisions from proposed Drugs Act for lapses
The existing Drugs and Cosmetics Act, 1940 is prosecutable. Any drug/cosmetic deemed to be adulterated or spurious is punishable with imprisonment and fine too. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2021 Category: Pharmaceuticals Source Type: news

SEC set to review Covaxin trial data for use in children
Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children under 18 years of age. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2021 Category: Pharmaceuticals Source Type: news

Piramal Enterprises board approves scheme for pharma biz demerger
The pharmaceuticals business will get demerged from Piramal Enterprises (PEL) and consolidated in Piramal Pharma, Piramal Enterprises said in a regulatory filing. The amalgamation of PHL Fininvest with PEL will create a listed non-banking financial services entity, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 7, 2021 Category: Pharmaceuticals Source Type: news

Danish pharma company Lundbeck downs shutters in India
The $2.7 billion Lundbeck, which is based out of Bengaluru, has a sales and marketing team of around 100 people in the country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 6, 2021 Category: Pharmaceuticals Source Type: news

Lupin gets tentative nod from USFDA to market generic Brexpiprazole tablets
The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market generic Brexpiprazole tablets in the strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, Lupin said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 6, 2021 Category: Pharmaceuticals Source Type: news

India's Bharat Biotech submits data on COVID-19 drug trial in children
Earlier, the WHO said it will take a call on granting Emergency Use Listing (EUL) status for Bharat Biotech's COVID-19 vaccine Covaxin next week. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 6, 2021 Category: Pharmaceuticals Source Type: news

AiSMA expresses concerns over government ’s decision to restrict syringe export
Rajiv Nath, President, All India Syringes and Needles Manufacturers Association (AiSNMA) urged the government to lift the restriction on non-covid sizes of syringes like Insulin syringes, 5 ml and larger syringe sizes or 0.3 ml AD syringes. “There are syringes developed specifically for other companies which can’t be used in India for vaccination and will be a wasted capacity otherwise,” he said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 5, 2021 Category: Pharmaceuticals Source Type: news

WHO to take final decision next week on approval to Bharat Biotech's Covaxin
The Emergency Use Listing process - done by WHO and the Technical Advisory Group of independent experts - is centred on determining if a manufactured product (e.g. a vaccine) is quality-assured, safe and effective, it said in another tweet. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 5, 2021 Category: Pharmaceuticals Source Type: news

WHO's Solidarity clinical trials: India to start trials of two new drugs to treat Covid-19
India is among the 52 countries taking part in WHO's Solidarity PLUS trial. This collaboration for Covid-19 research is also studying the effectiveness of another drug - Artesunate, which is used for treatment of severe malaria. The trials in some other countries will include this third drug. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 5, 2021 Category: Pharmaceuticals Source Type: news

Seventy per cent of India's adult population administered first dose COVID-19 vaccine: Mandaviya
With the administration of 23,46,176 vaccine doses in the last 24 hours, the cumulative COVID-19 vaccine doses administered has exceeded 90.79 crore as per provisional reports. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 4, 2021 Category: Pharmaceuticals Source Type: news

Temasek buys into True North-backed pharma firm Integrace
Integrace currently manages more than 20 brands and recently acquired two brands in Women ’s Health from Zydus Cadila. The company brands are market leaders in core orthopedic and gynecology segments like Bone and Joint disorders, Pain Management and, Pregnancy and Women’s Nutrition, said the press statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 4, 2021 Category: Pharmaceuticals Source Type: news

Phase-3 trials to begin on two-dose regimen
In a meeting held last month, the Subject Expert Committee (SEC), which advises the drug regulator-granted permission to the company for conducting Phase III trials on its vaccine. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 4, 2021 Category: Pharmaceuticals Source Type: news